Who are CHF 5259's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TELMINUVO Tab. (80/2.5mg), TEV-56248, VTS-K, SHR6390 Tablets, TAK-816, Group VTI.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chf-5259.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

CHF 5259 — Competitive Intelligence Brief

CHF 5259 (CHF 5259) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sodium-activated potassium channel inhibitor. Area: Cardiovascular.

phase 2 Sodium-activated potassium channel inhibitor KCNN4 Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

CHF 5259 (CHF 5259) — Chiesi Farmaceutici S.p.A.. CHF 5259 is a small molecule drug that acts as a selective inhibitor of the sodium-activated potassium channel, KCNN4.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CHF 5259 TARGET	CHF 5259	Chiesi Farmaceutici S.p.A.	phase 2	Sodium-activated potassium channel inhibitor	KCNN4
TELMINUVO Tab. (80/2.5mg)	TELMINUVO Tab. (80/2.5mg)	Chong Kun Dang Pharmaceutical	phase 3	Sodium-activated potassium channel inhibitor	KCNN4
TEV-56248	TEV-56248	Teva Branded Pharmaceutical Products R&D, Inc.	phase 3	sodium-activated potassium channel inhibitor	KCNN4
VTS-K	VTS-K	Maimonides Medical Center	marketed	sodium-activated potassium channel inhibitor	Nav1.6
SHR6390 Tablets	SHR6390 Tablets	Jiangsu HengRui Medicine Co., Ltd.	phase 3	Sodium-activated potassium channel inhibitor	Nav1.5
TAK-816	TAK-816	Takeda	phase 3	Sodium-activated potassium channel inhibitor	Nav1.5
Group VTI	Group VTI	Kasr El Aini Hospital	phase 3	sodium-activated potassium channel inhibitor	Nav1.5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sodium-activated potassium channel inhibitor class)

Chiesi Farmaceutici S.p.A. · 1 drug in this class
Chong Kun Dang Pharmaceutical · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Mylan Inc. · 1 drug in this class
Pfizer · 1 drug in this class
Syndeio Biosciences, Inc · 1 drug in this class
Takeda · 1 drug in this class
Teva Branded Pharmaceutical Products R&D, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CHF 5259 — Competitive Intelligence Brief. https://druglandscape.com/ci/chf-5259. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab